Clinical trials: Crohn Disease in Remission
Crohn's Disease
Remission in Subjects With Crohn's Disease, 1 Year Phase
The objectives were: (1) To demonstrate the efficacy of adalimumab in the maintenance of clinical remission up to 56 weeks in participants with Crohn's disease who participated in NCT00055523; (2) To delineate the safety of…
- Trial name
- CLASSICII (NCT00055497)
- Testing
- DB adalimumab 40 mg eow, DB adalimumab 40 mg ew, OL adalimumab 40 mg
- Where
- 43 sites in United States
- Volunteers
- 276 people
- Sponsor
- Abbott
Crohn's Disease
One Year Study of Rifaximin Delayed Release (DR) in Crohn's Disease
The primary objective is to determine the efficacy of rifaximin DR also referred to as Extended Intestinal Release (EIR) tablets vs.
- Trial name
- NCT02240108
- Testing
- Rifaximin EIR
- Where
- 78 sites in United States
- Volunteers
- 81 people
- Sponsor
- Bausch Health Americas, Inc.
Crohn's Disease
An Active Treatment Study to Induce Clinical Response and/or Remission With GSK1605786A in Subjects With Crohn's Disease
This is a multi-centre, randomised, double-blind, active treatment, parallel group induction study in subjects with moderately-to-severely active Crohn's disease.
- Trial name
- SHIELD-4 (NCT01536418)
- Testing
- GSK1605786A
- Where
- 227 sites in United States, Australia and 29 more
- Volunteers
- 255 people
- Sponsor
- GlaxoSmithKline
Crohn's Disease
Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease
The primary purpose of this study was to determine the effect of vedolizumab induction treatment on clinical response and remission at 6 weeks and to determine the effect of vedolizumab maintenance treatment on clinical remission…
- Trial name
- GEMINI II (NCT00783692)
- Testing
- vedolizumab
- Where
- 114 sites in United States, Canada and 1 more
- Volunteers
- 1,116 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Crohn's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of ABT-494 for the Induction of Symptomatic and Endoscopic Remission in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Immunomodulators or Anti-TNF Therapy
To determine the efficacy and safety of multiple doses of ABT-494 in subjects with moderately to severely active Crohn's Disease with a history of inadequate response to or intolerance to Immunomodulators or anti-Tumor Necrosis…
- Trial name
- NCT02365649
- Testing
- ABT-494
- Volunteers
- 220 people
- Sponsor
- AbbVie
Crohn Disease
Crohn Disease Exclusion Diet After Single Medication De-escalation
The primary objective of this study is to determine whether pediatric Crohn Disease (CD) patients in long-standing remission remain in remission longer after stopping medications if they follow the Crohn's Disease Exclusion Diet…
- Trial name
- CEASE (NCT02472457)
- Testing
- Crohn Disease Exclusion Diet, Free Diet
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Children's Hospital of Philadelphia
Crohn's Disease
A Study of Adalimumab for the Induction of Clinical Remission in Japanese Subjects With Crohn's Disease
The purpose of this study is to demonstrate the efficacy and safety of adalimumab for the induction of clinical remission in Japanese subjects with Crohn's disease.
- Trial name
- NCT00445939
- Testing
- adalimumab
- Where
- 18 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Abbott
Crohn's Disease
Remission in Subjects With Crohn's Disease, Open Label Extension
The objectives were: (1) To demonstrate the efficacy of adalimumab in the long-term maintenance of clinical remission in participants with Crohn's disease; and (2) To delineate the long-term safety of adalimumab when administered…
- Trial name
- CLASSICII (NCT01070303)
- Testing
- Adalimumab 40 mg eow or ew
- Where
- 43 sites in United States
- Volunteers
- 177 people
- Sponsor
- Abbott
Crohn Disease
Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease
An open label extension to the RHB-104-01 Study.
- Trial name
- MAPUS2 (NCT03009396)
- Testing
- RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
- Where
- 24 sites in United States, Canada and 5 more
- Volunteers
- 54 people
- Sponsor
- RedHill Biopharma Limited
Crohn's Disease
Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease
This study in patients with moderately to severely active Crohn's disease is designed to establish the efficacy and safety of vedolizumab for the induction of clinical response and remission.
- Trial name
- GEMINI III (NCT01224171)
- Testing
- vedolizumab
- Where
- 41 sites in United States, Canada
- Volunteers
- 416 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Crohn's Disease
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
This study will evaluate the efficacy and safety of adalimumab induction and maintenance treatment in subjects with moderately to severely active Crohn's disease in China.
- Trial name
- NCT02499783
- Testing
- adalimumab
- Volunteers
- 205 people
- Sponsor
- AbbVie
Crohn's Disease
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Crohn's Disease
The primary objectives of this study are to evaluate the safety and efficacy of filgotinib during induction and maintenance treatment of moderately to severely active Crohn's disease (CD) in participants who are biologic-naive…
- Trial name
- DIVERSITY1 (NCT02914561)
- Testing
- Filgotinib
- Where
- 513 sites in United States, Argentina and 39 more
- Volunteers
- 1,372 people
- Sponsor
- Lakefront Biotherapeutics NV
Crohn Disease, Pediatric Crohns Disease
Personalized AZithromycin/metronidAZole Therapy in Pediatric Crohn's Disease (CD)
This is a multi-center, randomized, controlled open-label add-on design trial pilot study to evaluate the efficacy of personalized adjunctive antibiotic (azithromycin + metronidazole) therapy in pediatric subjects with mild to…
- Trial name
- PAZAZ (NCT04186247)
- Testing
- Azithromycin, Metronidazole, Standard of Care
- Where
- 5 sites in United States, Canada and 2 more
- Volunteers
- 13 people
- Sponsor
- University of North Carolina, Chapel Hill
Crohn's Disease
Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease
This is a multi-centre, open-label extension study in subjects who showed clinical response to induction therapy in the treatment of subjects with active Crohn's disease in the double-blind main study C87037 (NCT00291668).
- Trial name
- NCT00329550
- Testing
- Certolizumab pegol (CZP)
- Where
- 23 sites in Japan
- Volunteers
- 40 people
- Sponsor
- UCB Japan Co. Ltd.
Crohn's Disease
Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease
The investigators hypothesize that RHB-104 will have greater efficacy than placebo in Crohn's disease.
- Trial name
- MAPUS (NCT01951326)
- Testing
- RHB-104
- Where
- 103 sites in United States, Australia and 8 more
- Volunteers
- 331 people
- Sponsor
- RedHill Biopharma Limited
Crohn's Disease
Study of Adalimumab Treatment for Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
The purpose of this study is to evaluate the safety of adalimumab for treatment of patients with moderate to severe Crohn's Disease (CD) and to measure the effects of treatment on patient general well-being, health-related…
- Trial name
- NCT00409617
- Testing
- adalimumab
- Where
- 189 sites in Austria, Belgium and 15 more
- Volunteers
- 945 people
- Sponsor
- Abbott
Crohn Disease
A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
The primary objective of the study is to assess the safety of long term therapy with Certolizumab Pegol in those subjects participating in study C87085 [NCT00552058].
- Trial name
- NCT00552344
- Testing
- Cimzia
- Where
- 100 sites in United States, Australia and 16 more
- Volunteers
- 403 people
- Sponsor
- UCB BIOSCIENCES GmbH
Crohn's Disease
One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease
The primary objective is to determine the efficacy of rifaximin DR also referred to as Extended Intestinal Release (EIR) tablets vs.
- Trial name
- NCT02240121
- Testing
- Rifaximin EIR
- Where
- 72 sites in United States
- Volunteers
- 80 people
- Sponsor
- Bausch Health Americas, Inc.
Crohn Disease
Trial of Specific Carbohydrate and Mediterranean Diets to Induce Remission of Crohn's Disease
This protocol is designed to compare the effectiveness of two dietary interventions for patients with Crohn's disease (CD): the Specific Carbohydrate Diet (SCD) and a Mediterranean style diet (MSD) that has been demonstrated to…
- Trial name
- DINE-CD (NCT03058679)
- Testing
- Diet
- Where
- 35 sites in United States
- Volunteers
- 197 people
- Sponsor
- University of Pennsylvania
Crohn's Disease, Inflammatory Bowel Disease
Corticosteroid Dosage for Crohn's Disease Flare
Prospective randomized comparative effectiveness trial designed to compare fixed dosing and weight-based dosing of corticosteroids in patients with Crohn's disease flares.
- Trial name
- NCT02392286
- Testing
- Corticosteroid
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Yale University